Skip Navigation


Annals of Oncology Advance Access originally published online on August 4, 2008
Annals of Oncology 2009 20(1):49-55; doi:10.1093/annonc/mdn545
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/1/49    most recent
mdn545v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Markopoulos, C.
Right arrow Articles by Gogas, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markopoulos, C.
Right arrow Articles by Gogas, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy

C. Markopoulos1,*, A. Polychronis2, U. Dafni1, D. Koukouras3, V. Zobolas4, E. Tzorakoleftherakis3, G. Xepapadakis5 and H. Gogas6

1 Department of Breast Surgery, Medical School, University of Athens, Athens
2 Department of Breast Surgery, 6th IKA Hospital, Athens
3 Department of Breast Surgery, University of Rio Patras, Patra
4 Department of Breast Surgery, Ag. Savas Anticancer Hospital, Athens
5 Department of Breast Surgery, Iaso General Hospital Athens, Athens
6 First Department of Medicine, University of Athens, Greece

* Correspondence to: Prof. C. Markopoulos, 8 Iassiou Street, 11521 Athens, Greece. Tel: +30-210-6862514; Fax: +30-210-6199943; E-mail: cmarkop{at}hol.gr

Background: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting.

Patients and methods: Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n = 77) or tamoxifen (n = 65). Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and serum triglyceride (TRG) levels were measured at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.

Results: A trend for a reduction in TC was found in both treatment arms; however, TC and LDL levels were consistently and significantly decreased in tamoxifen arm only. The mean HDL level was higher for the tamoxifen arm compared with the exemestane arm across time. No significant trend was detected throughout the study period on TRG levels on either arm.

Conclusions: Unlike tamoxifen's beneficial effect on TC and LDL levels, exemestane appears to have a neutral effect on lipidemic profile of postmenopausal, breast cancer patients. These data offer additional information with regard to the safety and tolerability of exemestane treatment in the adjuvant setting.

Key words: aromatase inhibitors, breast cancer, cholesterol, exemestane, lipids, tamoxifen, TEAM trial

Received for publication May 4, 2008. Revision received July 3, 2008. Accepted for publication July 4, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.